Abstract: Disclosed are a composition for inhibiting hyperlipidemia and obesity through suppression of intestinal cholesterol absorption. An IgY-type antibody derived from yolk to NPC1L1 (Niemann-Pick C1-Like1), contained, as an active ingredient, in the composition of the present invention is linked to NPC1L1 (Niemann-Pick C1-Like1) that is a cholesterol transport protein in the intestines, thus interfering with binding between cholesterol and the transport protein to completely block absorption of cholesterol in the body and thereby prevent hyperlipidemia and obesity.

Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.

Abstract: Provided herein are, inter alia, methods of diagnosing and treating autoimmune cardiomyopathy in subjects, based upon the detection of IgG4 autoantibodies to cardiac troponin I (cTnI).

Abstract: The invention relates to the use of a monovalent antibody fragment directed against the EC2 domain of the Fc?RI receptor for the treatment of inflammatory diseases.

Abstract: Piglet feed is supplemented with anti-E. coli K88 antibody-containing egg powder having a titer of the K88 antibodies of at least 1/256,000 as a means of improving growth performance of piglets.

Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

Abstract: Targeting molecules for use in delivering biological agents to epithelial tissue are disclosed. Upon delivery, the biological agent(s) may remain within an epithelial cell or may undergo transepithelial transport via transcytosis. The targeting molecules may be used, for example, for the delivery of therapeutic agents.

Abstract: An antivenom comprising a mixture of monospecific antisera each raised against venoms of one species or sub-species is disclosed. Also disclosed is a pharmaceutical composition comprising the antivenom of the invention, and a method of treating envenomation in a mammal comprising administering the claimed antivenom.

Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.

Abstract: A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a solid inorganic carrier material, (ii) IgA is isolated from the eluate, optionally after selective desorption, whereas IgG remains on the carrier material, and optionally (iii) IgG is isolated from the adsorbate. Furthermore, an IgA preparation is disclosed which demonstrates a low tendency to form aggregates.

Abstract: Effective antitoxins are demonstrated for prophylactic or causal immunotherapy. A method of generating antitoxin composed of highly-pure antibodies is described as an important defense against naturally-occurring plant and/or bacterial toxins.

Abstract: The prevention and treatment of autoimmune disease in humans (as well as other animals) is described through the use of ligands directed to cytokines. Antibodies and receptors to the proinflammatory cytokines IL-2, TNF, IL-12 and IFN-gamma are employed (along with other ligands to such cytokines). Such ligands administered luminally are effective (as demonstrated in two experimental models of autoimmune disease) at delaying the onset of autoimune disease.

Abstract: This invention includes the conception of T-independent conjugate-vaccines and its application in the induction of antigen specific IgA response. We demonstrated that 1) &agr;(1,6)dextran can elicit a markedly enhanced IgA response in T-cell free mice (20-50 fold higher than in normal mice); 2)co-injection of the molecule with other antigens can enhance the IgA response to the co-antigen; and 3)a dextran-Gag conjugate can elicit the Gag-specific IgA. Thus, the invention identified &agr;(1,6)dextran as a carrier molecule for producing the T-independent conjugates and as an adjuvant for the enhancement of IgA production. The T-independent property of these conjugates makes it especially useful in vaccinations against HIV and other infectious and non-infectious diseases associated with T-cell deficiency.

Abstract: An oral dosage composition for intestinal delivery of a therapeutic agent comprising:(A) a therapeutic agent selected from the group consisting of a drug compound, a biologically active peptide and a vaccine; and(B) an intestinal absorption enhancing effective amount of purified Vibrio cholera zonula occludens toxin.

Abstract: A method for increasing feed conversion efficiency in mammals, such as swine, wherein the mammal is fed a diet containing an antibody produced using the enzyme urease as the antigen.

Abstract: A method for lowering somatic cell count in the milk of a lactating ruminant is disclosed. IgY antibodies are first obtained from the egg of a hen which has been actively immunized against one or more mastitis-causing pathogenic organisms by injection with an immunogen containing immunogenic determinants specific to elicit such antibodies. The immunogenic determinant may comprise only a specific portion of the pathogenic organism, e.g., the fimbria of a piliated bacterium. The IgY antibodies are then administered orally to a ruminant in which it is desired to lower milk somatic cell count. Antibody administration may occur during a ruminant's dry period as well as during lactation. In a preferred embodiment, the antigen used in immunization of the hen comprises one or more of Staphylococcus aureus and Streptococcus agalactiae. The method of this invention has been shown to be efficacious in lowering somatic cell count in dairy cattle.

Abstract: Antivenoms suitable for treatment of humans and animals as well as for analytical use. A method wherein individual venoms are used to immunize and the resulting antivenoms are, thereafter, purified individually prior to mixing. Immunization is performed in a mammalian or avian host species.